Lupin launches generic joint pain drug in US market

Lupin launches generic joint pain drug in US market

The company's product- Diclofenac Sodium Topical Solution 2 per cent- is the generic version of Horizon Pharma Therapeutics Pennsaid

PTIUpdated: Friday, December 09, 2022, 03:17 PM IST
article-image
Image credit: Wikipedia (Representative)

Lupin announced on Friday that it has launched a generic version of Pennsaid, which is used to treat knee pain caused by osteoarthritis, in the American market.

The company's product- Diclofenac Sodium Topical Solution 2 per cent- is the generic version of Horizon Pharma Therapeutics Pennsaid, Lupin said in a statement.

As per IQVIA MAT October 2022 data, Lupin said diclofenac sodium topical solution, 2 per cent, had estimated annual sales of USD 509 million in the US.

RECENT STORIES

SEBI Streamlines Process For Grant Of Investor Accreditation Under AIF Regime

SEBI Streamlines Process For Grant Of Investor Accreditation Under AIF Regime

Silver Rebounds Nearly 3 Per Cent To ₹2.5 Lakh Per Kg; Gold Rises On Global Risk Concerns

Silver Rebounds Nearly 3 Per Cent To ₹2.5 Lakh Per Kg; Gold Rises On Global Risk Concerns

India Still Keen On US Trade Deal, MEA Rejects Commerce Secretary Lutnick’s Remarks | VIDEO

India Still Keen On US Trade Deal, MEA Rejects Commerce Secretary Lutnick’s Remarks | VIDEO

SEBI Eases Technical Glitch Framework For Stock Brokers

SEBI Eases Technical Glitch Framework For Stock Brokers

Mutual Fund Data For December Signals Maturing Investor Base: Analysts

Mutual Fund Data For December Signals Maturing Investor Base: Analysts